Maravai LifeSciences (MRVI) Tops Q4 EPS by 7c; Guides Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
Maravai LifeScience Holdings Inc. (MRVI) PT Lowered to $45 at Stifel
February 24, 2022 7:14 AM ESTStifel analyst Daniel Arias lowered the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $45.00 (from $56.00) while maintaining a Buy rating.
The analyst commented, "MRVI posted a solid top- and bottom-line beat driven by strength in CleanCap. Along with earnings, management provided... More
